SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

Date of Report: July 10, 2009

Date of Report: March 2, 2009

(Date of earliest event reported)

XECHEM INTERNATIONAL, INC.

(Exact name of registrant as specified in the charter)

Delaware	0-23788	22-3284403
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

Xechem International, Inc.

PO Box 327

Middletown, NJ 07748-0327

(732) 247-3300

Registrant’s telephone number including area code)

NOT APPLICABLE

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Resignation of Director.

Resignation of Martin Biggs from Board of Directors. Effective May 17, 2007 Dr. Martin Biggs was added to the Board of Directors of the Company by approval of a majority of the existing members of the Board of Directors, as the second of the nominees on behalf of the purchasers of Units comprised of Convertible Debentures plus Warrants pursuant to the Securities Purchase Agreement of the Company dated as of April 4, 2007. On March 2, 2009, Dr. Biggs resigned from the board and any further affiliation with the Company citing personal commitments that would no longer permit time to devote to Xechem.

Item 8.01 Other Events.

OnThe ~~November 10, 2008, Xechem International, Inc. (the "~~Company" ~~or "Xechem") and one of its subsidiaries, Xechem Inc.,~~ filed ~~voluntary petitions for relief under Chapter 11 of~~ the ~~United~~following ~~States~~self ~~Bankruptcy~~explanatory ~~Code~~letter inwith the ~~United~~Securities ~~States Bankruptcy~~and ~~Court~~Exchange ~~for~~Fraud ~~the~~Enforcement ~~Northern~~Division ~~District of Illinois (the "Bankruptcy Court") to suspend all litigation and to restructure its debt. A copy of the press release issued~~ on ~~that~~July ~~date~~10, ~~announcing the bankruptcy filing is attached.~~2009:

~~Demand Letter from the~~Xechem ~~Creditor~~International, ~~Committee~~Inc. ~~The~~ ("Company") ~~received~~is a ~~letter~~public ~~dated~~company. It ~~March~~has ~~10,~~come ~~2009~~to ~~from~~our ~~Charles~~attention ~~Ganz~~that Dr. Ramesh Pandey, ~~Vice-Chair~~CEO of the ~~Official~~Company ~~Committee~~from ofthe ~~unsecured~~time ~~Creditors~~it went ofpublic ~~Xechem~~in ~~International~~1994 until his removal in July 2007, ~~Inc~~may have filed fraudulent SEC documents. SEC documents filed and ~~Xechem,~~signed ~~Inc~~by Dr. ~~advising~~Pandey indicate that Xechem ~~there~~International ~~are~~owns ~~several causes~~2/3 of ~~action~~Xechem ~~that~~India ~~may~~Pvt, ~~exist~~Ltd. ~~which~~(“XIndia”) ~~should~~as beshown ~~preserved~~by the ~~for~~following statement from the ~~benefit~~10QSB offiled ~~the applicable~~in ~~estate~~2007, ~~including~~“(c) ~~against~~Xechem ~~all~~India ~~applicable~~is presently ~~persons,~~owned ~~entities~~66-2/3% by the Company and the remainder by Ramesh C. Pandey and ~~insurance~~family ~~coverage~~members”. AIt ~~portion~~was ofdiscovered ~~what~~in ~~the~~2007 ~~letter~~that ~~includes~~XIndia asis nearly 100% owned by Mr. Pandey and this was reported to the ~~following~~ ~~allegations:~~SEC. The ~~letter~~Company sent ~~has~~over ~~made~~$1 ~~allegations~~million ofto ~~fraud~~XIndia since 2000, which was used to buy land owned by ~~breach~~XIndia, pay employees, including members of ~~fiduciary~~Dr. ~~duty~~Pandey’s family and ~~inadequate~~other ~~disclosure~~uses. It was thought this situation could be resolved, ~~among~~however, ~~other~~as of July 10, 2009, ~~things~~the Company still does not have 2/3 ownership of XIndia per SEC filings.

~~The Company received letters~~On ~~from~~another ~~two~~matter, ~~holders of convertible debentures~~Dr. ~~The~~ ~~first~~Pandey ~~was~~filed ~~from counsel~~a to10QSB ~~an institutional investor~~ and ~~additional~~a ~~investors~~S3/A ~~with~~dated ~~regard~~8/14/02 toand a10/19/02, ~~Stock~~respectively, ~~Purchase~~stating ~~Agreement~~that ~~dated~~a ~~April~~drug 4,(NIPRISAN) ~~2007~~licensed (by the ~~“SPA”)~~Company ~~for~~from the National ~~purchase~~Institute ~~price~~ of ~~$4,959,663. The~~Pharmaceutical ~~letter~~Research ~~was~~and ~~addressed~~Development ~~specifically~~(NIPRD) ~~to Dr. Pandey.~~in ~~They~~Nigeria, ~~claim~~was ~~misrepresentations~~patented ~~and~~in ~~omissions~~46 ofcountries. This ~~material~~was ~~fact~~ in ~~connection~~accordance with ~~their~~the ~~investment~~statements ~~and~~in ~~that~~the ~~they~~NIPRD ~~are~~license ~~commencing~~agreement ansigned ~~action~~in ~~against~~July Dr2002. ~~Pandey.~~

~~The~~NIPRISAN ~~second~~has ~~letter~~been ~~was~~a ~~received~~major ~~from~~asset anof ~~individual~~the ~~investor~~Company onsince ~~behalf~~2002. The ofCompany ~~himself and~~has ~~all~~invested ~~similarly~~millions ~~situated~~of ~~holders~~dollars ofin ~~the~~Nigeria ~~Secured~~since ~~Convertible~~July ~~Debentures~~2003 ~~Due~~and ~~April~~investors relied on 4,the ~~2008,~~statements ~~placing~~found ain ~~demand~~the ~~for~~SEC ~~repayment~~filings of NIPRISAN patent protection when investing in the ~~Debentures~~Company. At ~~plus~~the ~~interest~~time ~~and~~of ~~lost~~signing the license ~~profits~~agreement ~~resulting~~with ~~from~~NIPRD ~~his~~in ~~investment~~July ~~and~~2002, ~~are~~there ~~seeking~~were ~~redress~~not ~~against~~46 ~~Ramesh~~patents ~~C Pandey~~covering NIPRISAN and ~~all~~Nigerian ~~who~~Government ~~participated~~Officials inknew ~~alleged~~or ~~negligence,~~should ~~misrepresentations~~have ~~and breaches~~known ~~of fiduciary duty~~this.

~~Item~~There is 9no evidence that Dr.01 Pandey knew about this constructive fraud when he signed the license agreement in July 2002 and filed SEC documents stating there were patents in 46 countries. ~~Exhibits~~Recently discovered Company documents, however, indicate that between July 2003 and July 2004 Dr. Pandey discovered there were not 46 patents covering NIPRISAN and failed to make this known to the public. Investors continued to rely on the earlier SEC filings when buying and selling the common stock and when investing over $10 million in convertible debt in the Company, under the belief there were 46 patents covering NIPRISAN.

Form of press release dated November 10, 2008 announcing bankruptcy filing of Xechem International, Inc.

Exhibit No.	Description
99.1	Press Release dated November 10, 2008

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Xechem International, Inc.
Dated: March 17, 2009	By:	/s/ Robert Swift
Dated: July 10, 2009	By:	/s/ Robert Swift
		Chief Oversight Officer

Filing Compare · XECHEM INTERNATIONAL INC